Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s

A new study has found that Eli Lilly’s obesity pill, tirzepatide, appears to be just as effective as injected GLP-1s in helping patients lose weight.

The study, which was published in the New England Journal of Medicine, involved over 1,200 participants who were given either tirzepatide or a placebo over the course of 40 weeks.

Participants who took tirzepatide lost an average of 20% of their body weight, while those who took the placebo lost only around 8%.

Tirzepatide works by mimicking the effects of GLP-1, a hormone that helps regulate appetite and blood sugar levels.

GLP-1s are currently only available as injections, so a pill version like tirzepatide could be a game-changer for patients who struggle with injections.

In addition to weight loss, participants who took tirzepatide also saw improvements in their blood sugar levels and other metabolic markers.

The results of this study are promising for the future of obesity treatment, as tirzepatide could offer a more convenient and effective option for patients looking to lose weight.

Further research will be needed to confirm these findings and assess the long-term effects of tirzepatide on weight loss and overall health.

Overall, the results of this study suggest that Eli Lilly’s obesity pill could be a valuable addition to the current treatments available for obesity and related conditions.